Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
INmune Bio, Inc. stock logo
INMB
INmune Bio
$2.30
$6.65
$1.89
$11.64
$54.25M1.34793,947 shs1.76 million shs
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
$0.00
$1.22
$8.45
$45.46M1.5329,344 shs80 shs
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
$4.10
+7.9%
$1.78
$1.11
$6.75
$538.31M2.331.62 million shs5.45 million shs
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
$3.18
+4.6%
$3.20
$2.65
$9.55
$168.22M0.85479,290 shs352,932 shs
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
INmune Bio, Inc. stock logo
INMB
INmune Bio
0.00%+10.05%-69.82%-69.86%-70.09%
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
0.00%0.00%0.00%0.00%+4,900.00%
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
+7.89%+50.18%+142.60%+228.00%-25.32%
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
+4.61%+1.92%-10.17%+2.25%-59.18%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
INmune Bio, Inc. stock logo
INMB
INmune Bio
1.5823 of 5 stars
3.30.00.00.02.01.70.6
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
4.0582 of 5 stars
4.41.00.00.03.85.00.6
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
3.8022 of 5 stars
3.61.00.04.62.00.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
INmune Bio, Inc. stock logo
INMB
INmune Bio
2.57
Moderate Buy$18.40700.00% Upside
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
0.00
N/AN/AN/A
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
2.75
Moderate Buy$10.08145.93% Upside
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
3.13
Buy$13.39321.07% Upside

Current Analyst Ratings Breakdown

Latest NBRV, PRME, INMB, and VYGR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/2/2025
INmune Bio, Inc. stock logo
INMB
INmune Bio
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$30.00 ➝ $8.00
7/1/2025
INmune Bio, Inc. stock logo
INMB
INmune Bio
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral
7/1/2025
INmune Bio, Inc. stock logo
INMB
INmune Bio
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Outperform ➝ Sector Underperform
6/30/2025
INmune Bio, Inc. stock logo
INMB
INmune Bio
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeModerate Buy ➝ Hold
5/27/2025
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$10.00 ➝ $1.50
5/20/2025
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Outperform ➝ Market Outperform$10.00 ➝ $6.00
5/20/2025
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
5/20/2025
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Neutral
5/19/2025
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$16.00 ➝ $12.00
(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
INmune Bio, Inc. stock logo
INMB
INmune Bio
$10K5,423.40N/AN/A$1.45 per share1.59
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
$35.59M0.00N/AN/A$0.10 per share0.00
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
$3.85M139.97N/AN/A$1.37 per share2.99
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
$80M2.20N/AN/A$5.49 per share0.58
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
INmune Bio, Inc. stock logo
INMB
INmune Bio
-$42.08M-$1.93N/AN/AN/AN/A-119.35%-89.37%7/30/2025 (Estimated)
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
-$57.19M-$19.20N/AN/AN/A-148.11%-365.53%-135.81%N/A
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
-$198.13M-$1.61N/AN/AN/AN/A-107.87%-74.97%N/A
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
-$65M-$1.46N/AN/AN/A-126.49%-27.36%-21.06%8/5/2025 (Estimated)

Latest NBRV, PRME, INMB, and VYGR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
-$0.48N/AN/AN/A$9.50 millionN/A
5/8/2025Q1 2025
INmune Bio, Inc. stock logo
INMB
INmune Bio
-$0.43-$0.43N/A-$0.43N/A$0.05 million
5/6/2025Q1 2025
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
-$0.35-$0.53-$0.18-$0.53$13.55 million$6.47 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
INmune Bio, Inc. stock logo
INMB
INmune Bio
N/AN/AN/AN/AN/A
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
N/AN/AN/AN/AN/A
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
$1.4535.27%N/AN/A N/A
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
INmune Bio, Inc. stock logo
INMB
INmune Bio
N/A
2.64
2.64
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
0.12
0.85
0.52
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
N/A
6.50
6.50
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
N/A
6.10
6.10

Institutional Ownership

CompanyInstitutional Ownership
INmune Bio, Inc. stock logo
INMB
INmune Bio
12.72%
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
0.27%
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
70.37%
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
48.03%

Insider Ownership

CompanyInsider Ownership
INmune Bio, Inc. stock logo
INMB
INmune Bio
35.70%
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
1.63%
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
22.93%
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
4.53%
CompanyEmployeesShares OutstandingFree FloatOptionable
INmune Bio, Inc. stock logo
INMB
INmune Bio
1023.58 million15.17 millionOptionable
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
7032.02 million31.49 millionNot Optionable
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
234131.29 million100.38 millionOptionable
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
10055.34 million52.83 millionOptionable

Recent News About These Companies

Atlas Announces New Canadian Arctic Expedition Aboard World Voyager
VYGR Voyager Therapeutics, Inc. - Seeking Alpha
Voyager Technologies Soars with IPO Success
Voyager Technologies Shares Soar In Market Debut
Voyager raises $383 million from upsized IPO

New MarketBeat Followers Over Time

Media Sentiment Over Time

INmune Bio stock logo

INmune Bio NASDAQ:INMB

$2.30 0.00 (0.00%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$2.28 -0.02 (-1.09%)
As of 08:49 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Nabriva Therapeutics stock logo

Nabriva Therapeutics NASDAQ:NBRV

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.

Prime Medicine stock logo

Prime Medicine NYSE:PRME

$4.10 +0.30 (+7.89%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$4.22 +0.12 (+2.80%)
As of 08:49 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.

Voyager Therapeutics stock logo

Voyager Therapeutics NASDAQ:VYGR

$3.18 +0.14 (+4.61%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$3.18 +0.00 (+0.16%)
As of 08:39 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.